Published in Cell on October 15, 2010
ARF family G proteins and their regulators: roles in membrane transport, development and disease. Nat Rev Mol Cell Biol (2011) 3.38
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet (2012) 1.96
EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol (2013) 1.77
Development of SNAP-tag fluorogenic probes for wash-free fluorescence imaging. Chembiochem (2011) 1.51
Cytohesins/ARNO: the function in colorectal cancer cells. PLoS One (2014) 1.45
Regulation of the catalytic activity of the EGF receptor. Curr Opin Struct Biol (2011) 1.26
Science publishing: The golden club. Nature (2013) 1.03
Small molecule-facilitated degradation of ANO1 protein: a new targeting approach for anticancer therapeutics. J Biol Chem (2014) 1.03
Regulation of developmental intercellular signalling by intracellular trafficking. EMBO J (2011) 0.91
Regulation of chandelier cell cartridge and bouton development via DOCK7-mediated ErbB4 activation. Cell Rep (2014) 0.90
ANO1 interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer. Oncotarget (2015) 0.89
Plakophilin-2 promotes tumor development by enhancing ligand-dependent and -independent epidermal growth factor receptor dimerization and activation. Mol Cell Biol (2014) 0.86
The N termini of a-subunit isoforms are involved in signaling between vacuolar H+-ATPase (V-ATPase) and cytohesin-2. J Biol Chem (2013) 0.83
Cytohesin-3 is upregulated in hepatocellular carcinoma and contributes to tumor growth and vascular invasion. Int J Clin Exp Pathol (2014) 0.81
Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells. PLoS One (2012) 0.80
Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor (EGFR) in cancer cells. Sci Rep (2014) 0.79
The ShcD signaling adaptor facilitates ligand-independent phosphorylation of the EGF receptor. Mol Biol Cell (2014) 0.78
Function and mode of action of cytohesins in the epidermal growth factor pathway in colorectal cancer cells. Oncol Lett (2012) 0.78
The cytohesin guanosine exchange factors (GEFs) are required to promote HGF-mediated renal recovery after acute kidney injury (AKI) in mice. Physiol Rep (2015) 0.78
ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. Cancer Cell (2016) 0.77
ERBB receptors in cancer: signaling from the inside. Breast Cancer Res (2011) 0.77
Attacking the supply wagons to starve cancer cells to death. FEBS Lett (2016) 0.77
Stepping stone: a cytohesin adaptor for membrane cytoskeleton restraint in the syncytial Drosophila embryo. Mol Biol Cell (2014) 0.76
Regulation of growth factor receptor degradation by ADP-ribosylation factor domain protein (ARD) 1. Proc Natl Acad Sci U S A (2011) 0.76
Ultrastructural Localization of Endogenous Exchange Factor for ARF6 in Adrenocortical Cells In Situ of Mice. Acta Histochem Cytochem (2016) 0.75
A luminescent oxygen channeling biosensor that measures small GTPase activation. Chem Commun (Camb) (2011) 0.75
Plakophilin-2 induced EGFR phosphorylation: a focus on the intracellular activators of EGFR. Receptors Clin Investig (2015) 0.75
Effect of IKZF1 deletions on signal transduction pathways in Philadelphia chromosome negative pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Exp Hematol Oncol (2015) 0.75
Design and Synthesis of New (SecinH3) Derivatives as Potential Cytohesin Inhibitors. Indian J Pharm Sci (2014) 0.75
Finding your inner activator. Nat Rev Cancer (2010) 0.75
Insider influence on ErbB activity. Cell (2010) 0.75
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Membrane fusion. Cell (2003) 7.68
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
An acylation cycle regulates localization and activity of palmitoylated Ras isoforms. Science (2005) 5.99
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell (2007) 4.85
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat Cell Biol (2007) 4.75
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol (2010) 4.19
Anatomy and dynamics of a supramolecular membrane protein cluster. Science (2007) 3.75
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res (2009) 3.13
Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science (2002) 3.12
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood (2005) 2.81
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer (2008) 2.76
EGFR activation coupled to inhibition of tyrosine phosphatases causes lateral signal propagation. Nat Cell Biol (2003) 2.49
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res (2008) 2.48
Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther (2009) 2.47
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res (2007) 2.45
Inhibition of cytohesins by SecinH3 leads to hepatic insulin resistance. Nature (2006) 2.40
Two-color nanoscopy of three-dimensional volumes by 4Pi detection of stochastically switched fluorophores. Nat Methods (2011) 2.28
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A (2006) 2.17
Munc18-bound syntaxin readily forms SNARE complexes with synaptobrevin in native plasma membranes. PLoS Biol (2006) 2.17
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol (2011) 2.10
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res (2011) 2.06
The SNARE motif is essential for the formation of syntaxin clusters in the plasma membrane. Biophys J (2006) 2.04
Imaging direct, dynamin-dependent recapture of fusing secretory granules on plasma membrane lawns from PC12 cells. Proc Natl Acad Sci U S A (2002) 2.03
Protein-dependent ribozymes report molecular interactions in real time. Nat Biotechnol (2002) 2.00
A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med (2011) 1.97
Activation of the p75 neurotrophin receptor through conformational rearrangement of disulphide-linked receptor dimers. Neuron (2009) 1.96
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res (2008) 1.95
The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med (2009) 1.95
High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One (2009) 1.93
Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nat Cell Biol (2009) 1.73
Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology (2011) 1.73
Plasmalemmal phosphatidylinositol-4,5-bisphosphate level regulates the releasable vesicle pool size in chromaffin cells. J Neurosci (2005) 1.71
Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One (2011) 1.65
Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol (2013) 1.65
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res (2012) 1.65
Homotypic fusion of early endosomes: SNAREs do not determine fusion specificity. Proc Natl Acad Sci U S A (2006) 1.59
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res (2006) 1.58
Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res (2012) 1.53
Aptamer displacement identifies alternative small-molecule target sites that escape viral resistance. Chem Biol (2007) 1.52
The cochaperone HspBP1 inhibits the CHIP ubiquitin ligase and stimulates the maturation of the cystic fibrosis transmembrane conductance regulator. Mol Biol Cell (2004) 1.52
Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol (2012) 1.50
Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol (2011) 1.49
GGA proteins regulate retrograde transport of BACE1 from endosomes to the trans-Golgi network. Mol Cell Neurosci (2005) 1.47
p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol (2009) 1.43
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res (2010) 1.43
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest (2013) 1.41
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res (2011) 1.40
Problems and promises of targeted therapy for Hodgkin's lymphoma. Nat Clin Pract Oncol (2005) 1.38
The R-SNARE motif of tomosyn forms SNARE core complexes with syntaxin 1 and SNAP-25 and down-regulates exocytosis. J Biol Chem (2003) 1.38
Enrichment of cell-targeting and population-specific aptamers by fluorescence-activated cell sorting. Angew Chem Int Ed Engl (2008) 1.35
Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem (2002) 1.35
Global analysis of time correlated single photon counting FRET-FLIM data. Opt Express (2009) 1.34
A versatile toolbox for variable DNA functionalization at high density. J Am Chem Soc (2005) 1.33
Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures. Nat Protoc (2010) 1.28
Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci Transl Med (2012) 1.28
Sequence-specific detection of MicroRNAs by signal-amplifying ribozymes. J Am Chem Soc (2004) 1.26
CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology (2008) 1.24
Coordinate-based colocalization analysis of single-molecule localization microscopy data. Histochem Cell Biol (2011) 1.23
Chemically induced photoswitching of fluorescent probes--a general concept for super-resolution microscopy. Molecules (2011) 1.22
Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res (2005) 1.22
A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci U S A (2012) 1.21
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst (2009) 1.21
GGA1 is expressed in the human brain and affects the generation of amyloid beta-peptide. J Neurosci (2006) 1.20
CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov (2014) 1.19
Aptamers for allosteric regulation. Nat Chem Biol (2011) 1.19
Cdt1 associates dynamically with chromatin throughout G1 and recruits Geminin onto chromatin. EMBO J (2007) 1.18
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov (2013) 1.18
Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Res (2010) 1.17
Conformational changes in the expression domain of the Escherichia coli thiM riboswitch. Nucleic Acids Res (2007) 1.17
CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate (2008) 1.16